Emedgene, Illumina partner on rare disease analysis

By The Science Advisory Board staff writers

December 16, 2020 -- Emedgene and Illumina have partnered to interpret genomic data for rare diseases.

Features from Emedgene's artificial intelligence (AI) powered Cognitive Genomics Intelligence were integrated into Illumina's TruSight software. TruSight enables sample-to-report analysis for genetic disease testing, allowing researchers to go from millions of variants to a small number in a rapid, scalable way. Together, they expect researchers will make new and unexpected discoveries, according to the companies.

Firms partner with Microsoft to advance DNA data storage
Twist Bioscience, Illumina, and Western Digital have formed an alliance with Microsoft to advance the field of DNA data storage.
Illumina's Q2 revenue drops 25%
Illumina's revenue dropped 25% due to the impact of the COVID-19 pandemic on the company's business in the second quarter. The company's net income also...
Illumina launches affordable sequencing kit for labs
Illumina has launched its NovaSeq 6000 v1.5 reagent kit, intended to make genome sequencing more accessible and affordable for labs of all sizes with...
Illumina introduces sequencing software for rare genetic diseases
Illumina has launched software that facilitates whole genome sequencing for rapid identification of rare genetic diseases.
Illumina Accelerator announces new genomics startups
Illumina has chosen seven companies to join the first global cohort of Illumina Accelerator, its startup incubator that partners with entrepreneurs to...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter